How does mismatch repair deficiency affect Colorectal Cancer treatment

How Mismatch Repair Deficiency Affects Colorectal Cancer Treatment

Mismatch repair (MMR) deficiency is one of the most important discoveries in colorectal cancer treatment because it fundamentally changes how doctors approach therapy. Let me explain what this means and why it matters for your care.

What is Mismatch Repair Deficiency?

Your cells have a "proofreading system" called mismatch repair (MMR) that catches and fixes mistakes when DNA is copied. When this system doesn't work properly—either because of inherited genetic changes (like Lynch syndrome) or because the cancer itself has damaged these genes—errors accumulate in the tumor's DNA.

This creates a pattern called microsatellite instability (MSI-H) or deficient mismatch repair (dMMR). These are two different ways of measuring the same problem, but they tell doctors important information about how your cancer will behave and respond to treatment.

According to the NCCN Guidelines for Colon Cancer, universal MMR or MSI testing is now recommended for all newly diagnosed colorectal cancer patients because the results directly influence treatment decisions.

How MMR Status Changes Treatment Strategy

For Early-Stage Disease (Stage II)

Here's where MMR status becomes particularly important:

If you have dMMR/MSI-H disease:

• Your cancer actually has a better prognosis (outlook) than MMR-proficient tumors
• The recurrence rate is lower—about 11% compared to 26% for MMR-proficient tumors
• Chemotherapy decisions are different: Research shows that patients with dMMR stage II disease may not benefit from standard fluoropyrimidine (5-FU) chemotherapy alone, and in some cases it may even be detrimental
• Your doctor may recommend immunotherapy instead or careful observation, depending on other risk factors

If you have proficient MMR (pMMR) disease:

• You're more likely to benefit from adjuvant (post-surgery) chemotherapy
• Standard chemotherapy regimens are typically recommended

For Advanced/Metastatic Disease (Stage IV)

This is where MMR status becomes truly transformative:

dMMR/MSI-H tumors respond dramatically to immunotherapy:

According to the NCCN Guidelines, patients with dMMR/MSI-H metastatic colorectal cancer are now eligible for checkpoint inhibitor immunotherapies, including:

• Pembrolizumab (Keytruda)
• Nivolumab (Opdivo)
• Dostarlimab (Jemperli)

These drugs work by "releasing the brakes" on your immune system. Here's the mechanism:

Why dMMR tumors respond to immunotherapy:

• The thousands of mutations in dMMR tumors create abnormal proteins that the immune system can recognize as "foreign"
• However, cancer cells produce PD-L1 and PD-L2 molecules that suppress immune response by binding to PD-1 receptors on immune cells
• Checkpoint inhibitors block this suppression, allowing your immune system to attack the cancer cells
• This approach has shown durable clinical benefit with significantly improved progression-free survival and overall survival compared to traditional chemotherapy

pMMR/MSS tumors (proficient mismatch repair):

• These typically don't respond as well to checkpoint inhibitors alone
• Standard chemotherapy combinations (like FOLFOX or FOLFIRI) remain the primary treatment
• EGFR-targeting monoclonal antibodies (cetuximab or panitumumab) may be considered if RAS and BRAF genes are wild-type (normal)

Additional Biomarkers That Work With MMR Status

Your doctor will also test for:

KRAS and BRAF mutations (especially important if you have pMMR disease):

• If you have a KRAS or NRAS mutation, you cannot receive cetuximab or panitumumab
• If you have a BRAF V600E mutation, response to EGFR inhibitors is highly unlikely unless combined with a BRAF inhibitor

HER2 amplification:

• If present (and you're RAS/BRAF wild-type), anti-HER2 therapies like trastuzumab may be recommended

Key Clinical Implications

| MMR Status | Stage II | Stage IV | |---|---|---| | dMMR/MSI-H | Better prognosis; may not need chemotherapy; consider immunotherapy if high-risk features | Checkpoint inhibitors (pembrolizumab, nivolumab, dostarlimab) are first-line options | | pMMR/MSS | Standard chemotherapy recommended | Chemotherapy ± EGFR inhibitors (if RAS/BRAF wild-type) |

Questions to Ask Your Oncologist

1. "What is my MMR/MSI status, and what does this mean for my specific treatment plan?"
2. "Based on my MMR status and other biomarkers (KRAS, BRAF, HER2), which treatment approach do you recommend and why?"
3. "If I have dMMR disease, am I a candidate for immunotherapy, and what are the expected response rates?"
4. "What are the side effects of the treatment you're recommending compared to alternatives?"
5. "How will we monitor my response to treatment, and how often will we reassess?"
6. "If my initial treatment doesn't work, what are the next options based on my biomarker profile?"

Why This Matters

The discovery that dMMR/MSI-H colorectal cancers respond to immunotherapy has been transformative. According to the NCCN Guidelines, this represents a fundamental shift from one-size-fits-all chemotherapy to precision medicine—tailoring treatment based on your tumor's specific genetic characteristics.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

---

Sources cited:

• NCCN Guidelines for Colon Cancer (Version 5.2025)
• NCCN Guidelines for Rectal Cancer (Version 4.2025)
• American Society of Clinical Oncology (ASCO) recommendations on molecular biomarkers